While technology advances were perhaps less dramatic than in the year prior, several firms teased future releases that could have significant impacts.
Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint
The guidance provides the agency's thoughts on the emerging use of ctDNA residual disease testing to select patients for treatment in trials of new adjuvant therapies.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
Oxford Nanopore Technologies Sues BGI, Affiliates for Sequencing Technology Contract Breach
Among other demands, Oxford Nanopore asked the UK court to grant an injunction to prevent the sale and licensing of BGI's nanopore sequencing products.
MiDiagnostics Closes €30M Series D Round Led by Thermo Fisher Scientific
The Belgium-based biotech firm will use the funding to further develop its sterility test for biopharma customers, leveraging its silicon chip-based qPCR technology.
According to the company, its research into organoids and mouse models of Alzheimer's disease has resulted in the detection of roughly 800 proteoforms of the protein tau.